OCA
Octagon Capital Advisors Portfolio holdings
AUM
$456M
This Quarter Return
+11.93%
1 Year Return
+48.55%
3 Year Return
+560.4%
5 Year Return
–
10 Year Return
–
AUM
$693M
AUM Growth
+$693M
(+8%)
Cap. Flow
+$53.8M
Cap. Flow
% of AUM
7.76%
Top 10 Holdings %
Top 10 Hldgs %
77.72%
Holding
45
New
13
Increased
8
Reduced
6
Closed
10
Top Buys
| 1 |
Roivant Sciences
ROIV
|
$28.8M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
$23.6M |
| 3 |
Jasper Therapeutics
JSPR
|
$11.6M |
| 4 |
Travere Therapeutics
TVTX
|
$11.1M |
| 5 |
Viridian Therapeutics
VRDN
|
$9.18M |
Top Sells
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$27.4M |
| 2 |
SPDR S&P Biotech ETF
XBI
|
$16.6M |
| 3 |
Viking Therapeutics
VKTX
|
$8.25M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$6.84M |
| 5 |
Arcus Biosciences
RCUS
|
$5.67M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apellis Pharmaceuticals
APLS
$3.48B
| $214M | 30.84% | 3,250,000 +90,000 | +3% | +$5.94M |
|
|
KDNY
2
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $59.1M | 8.5% | 2,551,703 | – | – |
|
|
VRNA
3
Verona Pharma
VRNA
$9.16B
| $49.6M | 7.13% | 2,468,000 | – | – |
|
|
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
| $39.9M | 5.73% | 4,570,918 +2,711,718 | +146% | +$23.6M |
|
|
5
Arcus Biosciences
RCUS
$1.13B
| $39.6M | 5.7% | 2,172,000 -310,700 | -13% | -$5.67M |
|
|
6
Viridian Therapeutics
VRDN
$1.5B
| $30.1M | 4.34% | 1,185,000 +360,800 | +44% | +$9.18M |
|
|
7
Roivant Sciences
ROIV
$8.15B
| $28.8M | 4.15% | +3,904,000 | New | +$28.8M |
|
|
MRTX
8
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $27.9M | 4.01% | 750,000 | – | – |
|
9
Celldex Therapeutics
CLDX
$1.47B
| $27.3M | 3.93% | 759,898 -1,500 | -0.2% | -$54K |
|
10
BridgeBio Pharma
BBIO
$9.89B
| $22.2M | 3.19% | 1,338,160 +404,417 | +43% | +$6.71M |
|
11
Tandem Diabetes Care
TNDM
$845M
| $19.3M | 2.78% | 474,929 | – | – |
|
|
JBIO
12
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $12.5M | 1.8% | 621,712 | – | – |
|
|
13
Jasper Therapeutics
JSPR
$45.5M
| $11.6M | 1.66% | +6,382,500 | New | +$11.6M |
|
|
14
Travere Therapeutics
TVTX
$1.56B
| $11.1M | 1.6% | +495,000 | New | +$11.1M |
|
|
ALPN
15
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $9.28M | 1.34% | 1,202,000 -23,000 | -2% | -$178K |
|
16
4D Molecular Therapeutics
FDMT
$288M
| $8.59M | 1.24% | 499,996 | – | – |
|
17
iTeos Therapeutics
ITOS
| $8.11M | 1.17% | 596,000 +151,000 | +34% | +$2.06M |
|
18
Dyne Therapeutics
DYN
$1.92B
| $7.98M | 1.15% | +692,945 | New | +$7.98M |
|
19
Xilio Therapeutics
XLO
$36.3M
| $7.69M | 1.11% | 2,425,000 | – | – |
|
|
20
Viking Therapeutics
VKTX
$3.04B
| $6.24M | 0.9% | 375,000 -495,500 | -57% | -$8.25M |
|
21
Vera Therapeutics
VERA
$1.38B
| $6.17M | 0.89% | 795,000 +129,844 | +20% | +$1.01M |
|
22
89bio
ETNB
$1.34B
| $6.09M | 0.88% | 400,000 +20,000 | +5% | +$305K |
|
23
Avidity Biosciences
RNA
$5.99B
| $5.86M | 0.84% | 382,000 +57,371 | +18% | +$881K |
|
|
ITCI
24
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $5.13M | 0.74% | 94,700 -126,253 | -57% | -$6.84M |
|
25
Geron
GERN
$893M
| $4.94M | 0.71% | +2,278,000 | New | +$4.94M |
|